Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)
Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination DPI in COPD
Sponsor: AstraZeneca
This observational or N/A phase trial investigates Chronic Obstructive Pulmonary Disease (COPD) and is currently completed. AstraZeneca leads this study, which shows 7 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Aug 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adana, Turkey (Türkiye), Afyonkarahisar, Turkey (Türkiye), Ankara, Turkey (Türkiye), Ayd?n, Turkey (Türkiye), Balıkesir, Turkey (Türkiye), Bartın, Turkey (Türkiye), Elâzığ, Turkey (Türkiye), Gaziantep, Turkey (Türkiye), Istanbul, Turkey (Türkiye), Izmir, Turkey (Türkiye) and 10 more location s